952480-19-2

Usage

Uses

Used in Pharmaceutical Synthesis:
(3R)-1-methylpiperidine-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its unique structural properties that facilitate the creation of diverse medicinal compounds.
Used in Organic Compounds Synthesis:
It serves as a building block in the synthesis of organic compounds, contributing to the development of new chemical entities with potential applications in various industries.
Used in Biological Research:
(3R)-1-methylpiperidine-3-carboxylic acid is utilized in biological research to explore its potential biological activities and pharmacological properties, with the aim of discovering new therapeutic agents or gaining insights into biological processes.
Used in Natural Products:
Found in certain plant species, (3R)-1-methylpiperidine-3-carboxylic acid is studied for its natural occurrence and potential benefits, which may lead to the development of novel natural health products or supplements.

Upstream product

• 499-04-7 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 205194-12-3 (R)-ethyl 1-methylpiperidine 3-carboxylate 
• 25137-01-3 (R)-ethyl nipecotate 
• 50-00-0 formaldehyd 
• 498-95-3 (R)-nipecotic acid 

Relevant academic research and scientific papers

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study

A series of potent HIV-1 protease inhibitors, containing diverse piperidine analogues as the P2-ligands, 4-substituted phenylsulfonamides as the P2'-ligands and a hydrophobic cyclopropyl group as the P1'-ligand, were designed, synthesized and evaluated in this work. Among these twenty-four target compounds, many of them exhibited excellent activity against HIV-1 protease with half maximal inhibitory concentration (IC50) values below 20 nM. Particularly, compound 22a containing a (R)-piperidine-3-carboxamide as the P2-ligand and a 4-methoxylphenylsulfonamide as the P2'-ligand exhibited the most effective inhibitory activity with an IC50 value of 3.61 nM. More importantly, 22a exhibited activity with inhibition of 42% and 26% against wild-type and Darunavir (DRV)-resistant HIV-1 variants, respectively. Additionally, the molecular docking of 22a with HIV-1 protease provided insight into the ligand-binding properties, which was of great value for further study.

SPIROPYRROLIDINES AND THEIR USE AGAINST HCV AND HIV INFECTION

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Enantioselective hydrogenation of arecaidine over cinchona alkaloid-modified palladium catalyst: A novel route to enantioenriched nipecotic acid derivatives

The hydrogenation of N-methyl-3,4-dehydronipecotic acid (arecaidine) over Pd/Al2O3 catalyst in presence of cinchona alkaloids and benzylamine additive results in the quantitative formation of N-methylnipecotic acid in good (up to 60%) optical purity. The reaction is a novel example of the efficient use of chirally modified heterogeneous metal catalysts allowing the preparation of enantioenriched N-heterocyclic carboxylic acids.